Brent L Saunders

Director

Brent L Saunders (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Bausch + Lomb Corporation (BLCO). Across 1 priced purchase filing, the average 21-session return was -5.0% from execution and -3.3% from disclosure (delay-adjusted; derived). The largest single filing was $252K of BLCO (14,700 sh × $17.14, as filed), executed Mar 6.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

-5.0%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

-3.3%

same 1 filings, from disclosure

Filings, ttm

1 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$252K

shares × price, as filed

Last traded

Mar 6

Filed Mar 10

Median ADV $7.4M across their filed names

Open performance→

Volume by month

Buys $500K Sells $1.7M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names

BLCO

Bausch + Lomb Corporation BLCO · 2 buys · 0 sells 2 filings SPRY SPRY SPRY · 0 buys · 1 sell 1 filing

Recent filings

BLCOPURCHASE Bausch + Lomb Corporation View filing → $252K
14,700 sh × $17.14
Exec Mar 6
Filed Mar 10 · 4:32 PM ET BLCOPURCHASE Bausch + Lomb Corporation View filing → $248K
22,000 sh × $11.28
Exec May 22 2025
Filed May 27 2025 · 5:30 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $1.7M
120,000 sh × $14.25
Exec May 20 2025
Filed May 22 2025 · 5:30 PM ET